vgx인터 관계사 이노비오 외신입니다.
Inovio, 자궁경부암백신 미국특허 취득. 임상2상 진행중
Inovio사는 인간유두종 바이러스에 의한 자궁경부암과 자궁경부 이형성증 치료 신콘백신에 대해 미국 특허상표국의 특허를 취득했다고 금일 발표했다.
-이노비오관련외신-
May 1, 2012, 4:00 a.m. EDT
Inovio Pharmaceuticals Granted U.S. Patent Protection for Synthetic Vaccine for Cervical Dysplasia and Cancer
Cancer Vaccine in Phase II Clinical Study
BLUE BELL, Pa., May 1, 2012 /PRNewswire via COMTEX/ -- Inovio Pharmaceuticals, Inc. /quotes/zigman/374264/quotes/nls/ino INO 0.00% announced today that the United States Patent and Trademark Office granted U.S. Patent No. 8,168,769, covering Inovio's SynCon?vaccine for cervical dysplasias and cancers caused by human papillomavirus (HPV). The patent granted to the Trustees of The University of Pennsylvania has been exclusively licensed to Inovio under its existing license agreement with the university. The patent includes claims that cover Inovio's synthetic consensus HPV antigens and DNA constructs and vaccines that include these antigens, including Inovio's cervical dysplasia/cancer vaccine, VGX-3100. This patent also covers methods of treating a patient using the SynCon?cervical dysplasia/cancer vaccine.
*** 본 정보는 투자 참고용 자료로서 그 정확성이나 완전성을 보장할 수 없으며, 어떠한 경우에도 법적 책임소재에 대한 증빙자료로 사용될 수 없습니다.